Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1

Julius Lukes Jr; Lucie Winkowska; Martina Zwyrtkova; Julia Starkova; Lucie Sramkova; Jan Stary; Jan Trka; Jan Zuna; Marketa Zaliova

doi:10.1097/HS9.0000000000000489

Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1

Hemasphere. 2020 Nov 10;4(6):e489. doi: 10.1097/HS9.0000000000000489. eCollection 2020 Dec.

Authors

Julius Lukes Jr^{1

2}, Lucie Winkowska^{1

2}, Martina Zwyrtkova^{1

2}, Julia Starkova^{1

2}, Lucie Sramkova^{1

2

3}, Jan Stary^{2

3}, Jan Trka^{1

2

3}, Jan Zuna^{1

2

3}, Marketa Zaliova^{1

2

3}

Affiliations

¹ CLIP - Childhood Leukemia Investigation Prague, Czech Republic.
² Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
³ University Hospital Motol, Prague, Czech Republic.

No abstract available